{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:19:18Z","timestamp":1792189158977,"version":"4.4.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014857","name":"National Natural Science Foundation of China-Guangdong Joint Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018536","name":"National Mega Project on Major Infectious Disease Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018536","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pneumocystis jiroveci\u00a0pneumonia (PJP) is the most common opportunistic infection in immunocompromised patients. The accurate prediction of PJP development in patients undergoing immunosuppressive therapy remains challenge.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients undergoing immunosuppressive treatment and with confirmed pneumocystis jiroveci infection were enrolled. Another group of matched patients with immunosuppressant treatment but without signs of infectious diseases were enrolled to control group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 80 (40 PJP, 40 non-PJP) participants were enrolled from Tongji Hospital. None of the patients were HIV positive. The routine laboratory indicators, such as LYM, MON, RBC, TP, and ALB, were significantly lower in PJP patients than in non-PJP patients. Conversely, LDH in PJP patients was significantly higher than in non-PJP controls. For immunological indicators, the numbers of T, B, and NK cells were all remarkably lower in PJP patients than in non-PJP controls, whereas the functional markers such as HLA-DR, CD45RO and CD28 expressed on CD4<jats:sup>+<\/jats:sup> or CD8<jats:sup>+<\/jats:sup> T cells had no statistical difference between these two groups. Cluster analysis showing that\u00a0decrease of host immunity markers including CD3<jats:sup>+<\/jats:sup>, CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T cells, and increase of tissue damage marker LDH were the most typical characteristics of PJP patients. A further established model based on combination of CD8<jats:sup>+<\/jats:sup> T cells and LDH showed prominent value in distinguishing PJP from non-PJP, with AUC of 0.941 (95% CI, 0.892-0.990).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A model based on combination of routine laboratory and immunological indicators shows prominent value for predicting the development of PJP in HIV-negative patients undergoing immunosuppressive therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.652383","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T05:06:17Z","timestamp":1618203977000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Using Routine Laboratory Markers and Immunological Indicators for Predicting Pneumocystis jiroveci Pneumonia in Immunocompromised Patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Guoxing","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiji","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S199761","article-title":"Clinical characteristics, treatment outcomes, and prognostic factors of Pneumocystis pneumonia in non-HIV-infected patients","volume":"12","author":"Liu","year":"2019","journal-title":"Infect Drug Resist"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-014-0459-z","article-title":"Pathological and protective immunity to Pneumocystis infection","volume":"37","author":"Eddens","year":"2015","journal-title":"Semin Immunopathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/cc6806","article-title":"Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection","volume":"12","author":"Monnet","year":"2008","journal-title":"Crit Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.2.573","article-title":"Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features","volume":"128","author":"Festic","year":"2005","journal-title":"Chest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.bpg.2017.03.001","article-title":"Modification of immunosuppressive therapy as risk factor for complications after liver transplantation","volume":"31","author":"De Simone","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12823","article-title":"Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy","volume":"186","author":"Rasche","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jcyt.2019.11.002","article-title":"High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era","volume":"22","author":"Evernden","year":"2020","journal-title":"Cytotherapy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.316","article-title":"The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis","volume":"51","author":"Williams","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102505","article-title":"Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis","volume":"19","author":"Thery-Casari","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.3390\/jcm9113573","article-title":"Is Routine Prophylaxis Against Pneumocystis jirovecii Needed in Liver Transplantation? A Retrospective Single-Centre Experience and Current Prophylaxis Strategies in Spain","volume":"9","author":"Fortea","year":"2020","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s42770-020-00277-2","article-title":"Characterization of Pneumocystis jirovecii pneumonia at three tertiary comprehensive hospitals in southern China","volume":"51","author":"Chen","year":"2020","journal-title":"Braz J Microbiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03174-15","article-title":"Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients","volume":"54","author":"Fauchier","year":"2016","journal-title":"J Clin Microbiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-007-7191-8","article-title":"Evaluation of Toluidine Blue O staining for the diagnosis of Pneumocystis jiroveci in expectorated sputum sample and bronchoalveolar lavage from HIV-infected patients in a tertiary care referral center in Ethiopia","volume":"36","author":"Aderaye","year":"2008","journal-title":"Infection"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0394-OA","article-title":"Gomori Methenamine Silver Stain on Bronchoalveolar Lavage Fluid Is Poorly Sensitive for Diagnosis of Pneumocystis jiroveci Pneumonia in HIV-Negative Immunocompromised Patients and May Lead to Missed or Delayed Diagnoses","volume":"144","author":"Azar","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.103.2.426","article-title":"Increased Pneumocystis carinii recovery from the upper lobes in Pneumocystis pneumonia. The effect of aerosol pentamidine prophylaxis","volume":"103","author":"Baughman","year":"1993","journal-title":"Chest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.06.010","article-title":"Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation","volume":"134","author":"Brakemeier","year":"2018","journal-title":"Pharmacol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2019.05.005","article-title":"Pneumocystis jirovecii pneumonia in children. A retrospective study in a single center over three decades","volume":"38","author":"Garcia-Moreno","year":"2020","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"B18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13613-019-0604-x","article-title":"Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study","volume":"9","author":"Gaborit","year":"2019","journal-title":"Ann Intensive Care"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03400.x","article-title":"Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients","volume":"17","author":"Alanio","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/prrv.2000.0007","article-title":"Bronchoalveolar lavage","volume":"1","author":"Connett","year":"2000","journal-title":"Paediatr Respir Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000487713","article-title":"Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia","volume":"96","author":"Salzer","year":"2018","journal-title":"Respiration"},{"key":"B22","doi-asserted-by":"publisher","first-page":"35(2017)","DOI":"10.1007\/s11926-017-0664-6","article-title":"Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented","volume":"19","author":"Wolfe","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.07.010","article-title":"Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients","volume":"127","author":"Fillatre","year":"2014","journal-title":"Am J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2012.08.024","article-title":"Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals","volume":"47","author":"Li","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00173-18","article-title":"Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy","volume":"62","author":"Quinn","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006150.pub2","article-title":"Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection","volume":"4","author":"Ewald","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e318281f562","article-title":"Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered","volume":"19","author":"Okafor","year":"2013","journal-title":"Inflammation Bowel Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32826fb6fc","article-title":"Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells\/microl when viral replication is suppressed","volume":"21","author":"D\u2019Egidio","year":"2007","journal-title":"AIDS"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705149","article-title":"Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study","volume":"36","author":"De Castro","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2017.1364991","article-title":"Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review","volume":"15","author":"Huang","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1513\/pats.201009-062WR","article-title":"Lung: HIV-associated Pneumocystis pneumonia","volume":"8","author":"Huang","year":"2011","journal-title":"Proc Am Thorac Soc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.02.010","article-title":"Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: Usefulness of lymphocyte subtyping","volume":"57","author":"Li","year":"2017","journal-title":"Int J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1583951","DOI":"10.1155\/2016\/1583951","article-title":"Plasma IL-6\/IL-10 Ratio and IL-8, LDH, and HBDH Level Predict the Severity and the Risk of Death in AIDS Patients with Pneumocystis Pneumonia","volume":"2016","author":"Sun","year":"2016","journal-title":"J Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/0148607100024006317","article-title":"Cytokine-driven inflammatory response is associated with the hypermetabolism of AIDS patients with opportunistic infections","volume":"24","author":"Garcia-Lorda","year":"2000","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00322-19","article-title":"Beta-d-Glucan for Diagnosing Pneumocystis Pneumonia: A Direct Comparison between the Wako beta-Glucan Assay and the Fungitell Assay","volume":"57","author":"Mercier","year":"2019","journal-title":"J Clin Microbiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2015.00264","article-title":"Commentary: Targeting LDH enzymes with a stiripentol analog to treat epilepsy","volume":"9","author":"Cho","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.02.005","article-title":"Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer","volume":"23","author":"Zhao","year":"2013","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1038\/s41598-018-22886-6","article-title":"Value of Preoperative Modified Body Mass Index in Predicting Postoperative 1-Year Mortality","volume":"8","author":"Oh","year":"2018","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9665-6","article-title":"Albumin in chronic liver disease: structure, functions and therapeutic implications","volume":"10","author":"Spinella","year":"2016","journal-title":"Hepatol Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.05.558","article-title":"Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases","volume":"158","author":"Ghembaza","year":"2020","journal-title":"Chest"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1038\/s41467-020-17491-z","article-title":"Gasdermin-D-dependent IL-1alpha release from microglia promotes protective immunity during chronic Toxoplasma gondii infection","volume":"11","author":"Batista","year":"2020","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.652383\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T05:06:19Z","timestamp":1618203979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.652383\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2021.652383"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.652383","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"article-number":"652383"}}